Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Nuclear hormone receptor family member nhr-41 | 0.0058 | 0.5 | 0.5 |
Echinococcus multilocularis | COUP TF:Svp nuclear hormone receptor | 0.0058 | 0.5 | 0.5 |
Brugia malayi | photoreceptor-specific nuclear receptor | 0.0058 | 0.5 | 0.5 |
Brugia malayi | Nuclear hormone receptor family member nhr-25 | 0.0058 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0058 | 0.5 | 0.5 |
Schistosoma mansoni | coup transcription factor | 0.0058 | 0.5 | 0.5 |
Echinococcus granulosus | FTZ F1 alpha | 0.0058 | 0.5 | 0.5 |
Schistosoma mansoni | photoreceptor-specific nuclear receptor related | 0.0058 | 0.5 | 0.5 |
Echinococcus multilocularis | nuclear receptor 2DBD gamma | 0.0058 | 0.5 | 0.5 |
Schistosoma mansoni | thyroid hormone receptor | 0.0058 | 0.5 | 0.5 |
Echinococcus multilocularis | nuclear receptor 2DBD gamma | 0.0058 | 0.5 | 0.5 |
Brugia malayi | Nuclear hormone receptor family member nhr-1 | 0.0058 | 0.5 | 0.5 |
Echinococcus granulosus | ecdysone induced protein 78C | 0.0058 | 0.5 | 0.5 |
Schistosoma mansoni | nuclear hormone receptor nor-1/nor-2 | 0.0058 | 0.5 | 0.5 |
Echinococcus granulosus | retinoic acid receptor rxr beta a | 0.0058 | 0.5 | 0.5 |
Loa Loa (eye worm) | nuclear hormone receptor family member nhr-40 | 0.0058 | 0.5 | 0.5 |
Echinococcus multilocularis | hepatocyte nuclear factor 4 alpha | 0.0058 | 0.5 | 0.5 |
Brugia malayi | Ligand-binding domain of nuclear hormone receptor family protein | 0.0058 | 0.5 | 0.5 |
Brugia malayi | Nuclear hormone receptor family member nhr-14 | 0.0058 | 0.5 | 0.5 |
Brugia malayi | Nuclear hormone receptor family member nhr-3 | 0.0058 | 0.5 | 0.5 |
Echinococcus multilocularis | Nuclear hormone receptor family member nhr 41 | 0.0058 | 0.5 | 0.5 |
Brugia malayi | Ligand-binding domain of nuclear hormone receptor family protein | 0.0058 | 0.5 | 0.5 |
Brugia malayi | Nuclear hormone receptor family member nhr-40 | 0.0058 | 0.5 | 0.5 |
Schistosoma mansoni | FTZ-F1 nuclear receptor-like protein | 0.0058 | 0.5 | 0.5 |
Loa Loa (eye worm) | steroid hormone receptor | 0.0058 | 0.5 | 0.5 |
Brugia malayi | Nuclear hormone receptor family member nhr-49 | 0.0058 | 0.5 | 0.5 |
Brugia malayi | Nuclear hormone receptor family member nhr-31 | 0.0058 | 0.5 | 0.5 |
Schistosoma mansoni | retinoic acid receptor RXR | 0.0058 | 0.5 | 0.5 |
Loa Loa (eye worm) | nuclear hormone receptor family member nhr-31 | 0.0058 | 0.5 | 0.5 |
Echinococcus granulosus | hepatocyte nuclear factor 4 alpha | 0.0058 | 0.5 | 0.5 |
Brugia malayi | Nuclear hormone receptor-like 1 | 0.0058 | 0.5 | 0.5 |
Echinococcus multilocularis | thyroid hormone receptor alpha | 0.0058 | 0.5 | 0.5 |
Echinococcus granulosus | Nuclear hormone receptor family member nhr 41 | 0.0058 | 0.5 | 0.5 |
Echinococcus granulosus | nuclear receptor 2DBD gamma | 0.0058 | 0.5 | 0.5 |
Echinococcus granulosus | FTZ F1 nuclear receptor protein | 0.0058 | 0.5 | 0.5 |
Schistosoma mansoni | retinoid-x-receptor (RXR) | 0.0058 | 0.5 | 0.5 |
Schistosoma mansoni | nuclear receptor 2DBD-gamma | 0.0058 | 0.5 | 0.5 |
Brugia malayi | Nuclear hormone receptor family member nhr-19 | 0.0058 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0058 | 0.5 | 0.5 |
Brugia malayi | Nuclear hormone receptor family member nhr-25 | 0.0058 | 0.5 | 0.5 |
Echinococcus multilocularis | FTZ F1 nuclear receptor protein | 0.0058 | 0.5 | 0.5 |
Loa Loa (eye worm) | nuclear hormone receptor family member nhr-49 | 0.0058 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0058 | 0.5 | 0.5 |
Loa Loa (eye worm) | nuclear hormone receptor family member nhr-1 | 0.0058 | 0.5 | 0.5 |
Schistosoma mansoni | thyroid hormone receptor | 0.0058 | 0.5 | 0.5 |
Schistosoma mansoni | nuclear hormone receptor | 0.0058 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0058 | 0.5 | 0.5 |
Onchocerca volvulus | 0.0058 | 0.5 | 0.5 | |
Schistosoma mansoni | RAR-like nuclear receptor | 0.0058 | 0.5 | 0.5 |
Echinococcus granulosus | nuclear receptor 2DBD gamma | 0.0058 | 0.5 | 0.5 |
Onchocerca volvulus | Steroid hormone receptor family member cnr14 homolog | 0.0058 | 0.5 | 0.5 |
Brugia malayi | nuclear receptor NHR-88 | 0.0058 | 0.5 | 0.5 |
Brugia malayi | steroid hormone receptor | 0.0058 | 0.5 | 0.5 |
Onchocerca volvulus | Bile acid receptor homolog | 0.0058 | 0.5 | 0.5 |
Echinococcus multilocularis | FTZ F1 alpha | 0.0058 | 0.5 | 0.5 |
Echinococcus multilocularis | ecdysone induced protein 78C | 0.0058 | 0.5 | 0.5 |
Schistosoma mansoni | steroid hormone receptor ad4bp | 0.0058 | 0.5 | 0.5 |
Onchocerca volvulus | Protein ultraspiracle homolog | 0.0058 | 0.5 | 0.5 |
Brugia malayi | Nuclear hormone receptor family member nhr-19 | 0.0058 | 0.5 | 0.5 |
Echinococcus granulosus | COUP TF:Svp nuclear hormone receptor | 0.0058 | 0.5 | 0.5 |
Loa Loa (eye worm) | nuclear hormone receptor family member nhr-41 | 0.0058 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0058 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0058 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0058 | 0.5 | 0.5 |
Loa Loa (eye worm) | nuclear hormone receptor family member nhr-14 | 0.0058 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0058 | 0.5 | 0.5 |
Brugia malayi | Steroid receptor seven-up type 2 | 0.0058 | 0.5 | 0.5 |
Schistosoma mansoni | Tr4/Tr2 (homologue) | 0.0058 | 0.5 | 0.5 |
Brugia malayi | nuclear hormone receptor | 0.0058 | 0.5 | 0.5 |
Loa Loa (eye worm) | nuclear Hormone Receptor family member | 0.0058 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 9.06 % | Analgesic activity in ICR mouse assessed as increase in pain threshold at 0.05 mmol/kg, po after 180 mins by tail flick method (Rvb = 8.75 +/- 9.73 %) | ChEMBL. | 21474215 |
Activity (functional) | = 11.55 % | Analgesic activity in ICR mouse assessed as increase in pain threshold at 0.05 mmol/kg, po after 30 mins by tail flick method (Rvb = 5.03 +/- 10.26 %) | ChEMBL. | 21474215 |
Activity (functional) | = 14.38 % | Analgesic activity in ICR mouse assessed as increase in pain threshold at 0.10 mmol/kg, po after 180 mins by tail flick method (Rvb = 8.75 +/- 9.73 %) | ChEMBL. | 21474215 |
Activity (functional) | = 15.43 % | Analgesic activity in ICR mouse assessed as increase in pain threshold at 0.05 mmol/kg, po after 150 mins by tail flick method (Rvb = 9.02 +/- 12.19 %) | ChEMBL. | 21474215 |
Activity (functional) | = 18.99 % | Analgesic activity in ICR mouse assessed as increase in pain threshold at 0.05 mmol/kg, po after 120 mins by tail flick method (Rvb = 8.09 +/- 13.28 %) | ChEMBL. | 21474215 |
Activity (functional) | = 21.39 % | Analgesic activity in ICR mouse assessed as increase in pain threshold at 0.10 mmol/kg, po after 150 mins by tail flick method (Rvb = 9.02 +/- 12.19 %) | ChEMBL. | 21474215 |
Activity (functional) | = 23.08 % | Analgesic activity in ICR mouse assessed as increase in pain threshold at 0.10 mmol/kg, po after 120 mins by tail flick method (Rvb = 8.09 +/- 13.28 %) | ChEMBL. | 21474215 |
Activity (functional) | = 23.58 % | Analgesic activity in ICR mouse assessed as increase in pain threshold at 0.05 mmol/kg, po after 90 mins by tail flick method (Rvb = 7.53 +/- 11.54 %) | ChEMBL. | 21474215 |
Activity (functional) | = 25.69 % | Analgesic activity in ICR mouse assessed as increase in pain threshold at 0.15 mmol/kg, po after 180 mins by tail flick method (Rvb = 8.75 +/- 9.73 %) | ChEMBL. | 21474215 |
Activity (functional) | = 26.54 % | Analgesic activity in ICR mouse assessed as increase in pain threshold at 0.05 mmol/kg, po after 60 mins by tail flick method (Rvb = 7.45 +/- 8.03 %) | ChEMBL. | 21474215 |
Activity (functional) | = 29.04 % | Analgesic activity in ICR mouse assessed as increase in pain threshold at 0.15 mmol/kg, po after 150 mins by tail flick method (Rvb = 9.02 +/- 12.19 %) | ChEMBL. | 21474215 |
Activity (functional) | = 32.32 % | Analgesic activity in ICR mouse assessed as increase in pain threshold at 0.10 mmol/kg, po after 30 mins by tail flick method (Rvb = 5.03 +/- 10.26 %) | ChEMBL. | 21474215 |
Activity (functional) | = 34.48 % | Analgesic activity in ICR mouse assessed as increase in pain threshold at 0.10 mmol/kg, po after 60 mins by tail flick method (Rvb = 7.45 +/- 8.03 %) | ChEMBL. | 21474215 |
Activity (functional) | = 38.33 % | Analgesic activity in ICR mouse assessed as increase in pain threshold at 0.10 mmol/kg, po after 90 mins by tail flick method (Rvb = 7.53 +/- 11.54 %) | ChEMBL. | 21474215 |
Activity (functional) | = 41.28 % | Analgesic activity in ICR mouse assessed as increase in pain threshold at 0.15 mmol/kg, po after 120 mins by tail flick method (Rvb = 8.09 +/- 13.28 %) | ChEMBL. | 21474215 |
Activity (functional) | = 44.27 % | Analgesic activity in ICR mouse assessed as increase in pain threshold at 0.15 mmol/kg, po after 30 mins by tail flick method (Rvb = 5.03 +/- 10.26 %) | ChEMBL. | 21474215 |
Activity (functional) | = 52.22 % | Analgesic activity in ICR mouse assessed as increase in pain threshold at 0.15 mmol/kg, po after 60 mins by tail flick method (Rvb = 7.45 +/- 8.03 %) | ChEMBL. | 21474215 |
Activity (functional) | = 54.39 % | Analgesic activity in ICR mouse assessed as increase in pain threshold at 0.15 mmol/kg, po after 90 mins by tail flick method (Rvb = 7.53 +/- 11.54 %) | ChEMBL. | 21474215 |
Inhibition (functional) | = 28.3 % | Antiinflammatory activity in ICR mouse assessed as inhibition of xylene-induced ear edema at 0.05 mmol/kg, po administered 30 mins before xylene challenge measured after 2 hrs relative to control | ChEMBL. | 21474215 |
Inhibition (functional) | = 45.4 % | Antiinflammatory activity in ICR mouse assessed as inhibition of xylene-induced ear edema at 0.10 mmol/kg, po administered 30 mins before xylene challenge measured after 2 hrs relative to control | ChEMBL. | 21474215 |
Inhibition (functional) | = 55.2 % | Antiinflammatory activity in ICR mouse assessed as inhibition of xylene-induced ear edema at 0.15 mmol/kg, po administered 30 mins before xylene challenge measured after 2 hrs relative to control | ChEMBL. | 21474215 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.